BCL2L11 Antibody

Catalog Number:

32068

Amount:

100μg

Price:

$319

Swiss-Prot No:

Swiss-Prot:O43521
NCBI Gene ID:10018

Form of Antibody:

Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability:

Immunogen:

Recombinant protein of human BCL2L11 .

Purification:

Antibodies were purified by affinity purification using immunogen.

Specificity/Sensitivity:

The antibody detects endogenous level of total BCL2L11 protein.

Applications:

IHC,IF

Background:

BCL2L11/Bod is a pro-apoptotic protein belonging to the BH3-only group of Bcl-2 family members including Bad, Bid, Bik, Hrk and Noxa that contain a BH3 domain but lack other conserved BH1 or BH2 domains (1,2). BCL2L11 induces apoptosis by binding to and antagonizing anti-apoptotic members of the Bcl-2 family. Interactions have been observed with Bcl-2, Bcl-xL, Mcl-1, Bcl-w, Bfl-1 and BHRF-1 (1,2). BCL2L11 functions in regulating apoptosis associated with thymocyte negative selection and following growth factor withdrawal, during which BCL2L11 expression is elevated (3-6). Three major isoforms of BCL2L11 are generated by alternative splicing: BCL2L11EL, BCL2L11L and BCL2L11S (1). The shortest form, BCL2L11S, is the most cytotoxic and is generally only transiently expressed during apoptosis. The BCL2L11EL and BCL2L11L isoforms may be sequestered to the dynein motor complex through an interaction with the dynein light chain and released from this complex during apoptosis (7). Apoptotic activity of these longer isoforms may be regulated by phosphorylation (8,9). Environmental stress triggers BCL2L11 phosphorylation by JNK and results in its dissociation from the dynein complex and increased apoptotic activity.

References:

appl_detail:

IHC 1:50 - 1:100
IF 1:50 - 1:100

Datasheet PDF